Super Religare Laboratories

The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.

So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.

The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.